(Q73231229)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

meta-analysis

0 references

title

Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

metastatic breast cancer

1 reference

M Robain

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J Y Pierga

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M Jouve

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

B Asselain

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

V Diéras

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P Beuzeboc

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

T Palangié

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

T Dorval

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J M Extra

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S Scholl

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P Pouillart

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 December 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

2301-2312

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Improved survival of patients with metastatic breast cancer receiving combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

P-glycoprotein expression in treated and untreated human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Chemotherapy of advanced breast cancer: outcome and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Clinical course and prognostic factors following bone recurrence from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Multivariate analysis of prognostic factors in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Clinical course of breast cancer patients with liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Construction and validation of a practical prognostic index for patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Steroid-hormone receptors and survival after first relapse in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Classification of patients with disseminated cancer of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Survival patterns in hormone treated advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900325-7

7 January 2021

10.1016/S0959-8049(00)00325-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11094303%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference